Pertaining IHC phenotypes, only 7 out of 23 (33.3%, two with missing IHC results) basal-like breast cancers were clinically triple negative (HR−/HER2−), while for 28 HER2-enriched breast cancers, 22 (81.5%, one with missing IHC result) were clinically HER2+. Here, ERBB2 is linked to breast carcinoma.